Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Frontiers in Oncology

Oncology

Carmen Wängler¹  Franziska J. Dekorsy²  Lena M. Unterrainer²  Ralf S. Eschbach²  Matthias Brendel²  Vera Wenter²  Lukas Späth²  Simon Lindner²  Astrid Delker²  Reinhold Tiling²  Gabriel T. Sheikh²  Markus Hofmann²  Mathias J. Zacherl²  Freba Grawe³  Andrei Todica⁴  Leonie Beyer⁴  Peter Bartenstein⁴  Harun Ilhan⁴  Ralf Schirrmacher⁵  Clemens C. Cyran⁶  Marcus Unterrainer⁶  Johannes Rübenthaler⁶  Stefan Boeck⁷  Christoph Benedikt Westphalen⁷  Christoph J. Auernhammer⁸  Christine Spitzweg⁸  Tanja Paul⁹  Thomas Knösel⁹  Klaus Jurkschat^1,10  Björn Wängler^1,11 

[1] Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany;Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;Department of Radiology, University Hospital, LMU Munich, Munich, Germany;Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany;Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB, Canada;Department of Radiology, University Hospital, LMU Munich, Munich, Germany;ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany;Department of Internal Medicine 3, University Hospital, Munich, Germany;ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany;Department of Internal Medicine 4, University Hospital, LMU Munich, Munich, Germany;ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany;Institute of Pathology, LMU, Munich, Germany;Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany;Medical Faculty Mannheim of Heidelberg University, Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Mannheim, Germany;

关键词: NET;    PET/CT;    [F]SiTATE;    somatostatin analogues;    somatostatin receptor;    molecular imaging;   

DOI  :  10.3389/fonc.2023.992316

 received in 2022-07-12, accepted in 2023-01-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

PurposeSomatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.Methods77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups.ResultsSUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05).ConclusionIn patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.

【 授权许可】

Unknown   
Copyright © 2023 Eschbach, Hofmann, Späth, Sheikh, Delker, Lindner, Jurkschat, Wängler, Wängler, Schirrmacher, Tiling, Brendel, Wenter, Dekorsy, Zacherl, Todica, Ilhan, Grawe, Cyran, Unterrainer, Rübenthaler, Knösel, Paul, Boeck, Westphalen, Spitzweg, Auernhammer, Bartenstein, Unterrainer and Beyer